Open Orphan launches hVIVO’s Covid-19 Clear Test
The specialist pharmaceutical services company said the antibody tests utilise the Quotient MosaiQ™ system and MosaiQ COVID-19 Antibody Microarray and require a full blood draw.
The group said the hVIVO COVID Clear Test will be offered to large employer groups and channel partners including GP networks, nursing services, health clinics and private hospitals.
Shares in Open Orphan closed at 14.45p on Wednesday afternoon.
Samples will be tested in the company's London laboratory with results returned within 48 hours, this morning’s statement explained.
"hVIVO is a world class company with best in class scientists and facilities,” said Cathal Friel, Executive Chairman of Open Orphan.
He added, “We are very excited to be offering this service and I am confident our work will help large companies and clinics in the UK test their staff and patients to ensure the safety of all employees.”
"Antibody testing is crucial for guidance on immunity, development of vaccinations and potential revaccinations, as well as helping to answer outstanding epidemiological questions about the spread of the virus,” said Franz Walt, Chief Executive of Quotient.
Follow News & Updates from Open Orphan here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.